Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen For Treatment Of Locally Advanced Pancreatic Cancer

Author: Benzinga Newsdesk | January 24, 2024 10:12am

Posted In: AIM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist